×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MIST – milestone pharmaceuticals inc. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MIST
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/3
07:26 am
mist
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "hold" rating.
Medium
Report
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "hold" rating.
4/2
04:35 pm
mist
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst [Yahoo! Finance]
Low
Report
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst [Yahoo! Finance]
4/2
08:59 am
mist
Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen [Yahoo! Finance]
Neutral
Report
Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen [Yahoo! Finance]
4/1
02:05 pm
mist
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was downgraded by analysts at TD Securities from a "buy" rating to a "hold" rating.
Low
Report
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was downgraded by analysts at TD Securities from a "buy" rating to a "hold" rating.
3/20
08:00 am
mist
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
Medium
Report
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
3/17
11:20 am
mist
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
3/13
07:08 am
mist
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
Medium
Report
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
3/4
08:00 am
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
09:03 am
MIST
milestone pharmaceuticals inc. - common shares
BEAT
Report
-3.7%
milestone pharmaceuticals inc. - common shares
8/8/2024
04:17 pm
MIST
milestone pharmaceuticals inc. - common shares
BEAT
Report
0.0%
milestone pharmaceuticals inc. - common shares
5/13/2024
07:15 am
MIST
milestone pharmaceuticals inc. - common shares
BEAT
Report
-1.2%
milestone pharmaceuticals inc. - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/19
04:05 pm
mist
Form 8-K Milestone Pharmaceutical For: Mar 18
Low
Report
Form 8-K Milestone Pharmaceutical For: Mar 18
3/18
05:04 pm
mist
Form 424B5 Milestone Pharmaceutical
High
Report
Form 424B5 Milestone Pharmaceutical
3/18
04:25 pm
mist
Form 8-K Milestone Pharmaceutical For: Mar 18
High
Report
Form 8-K Milestone Pharmaceutical For: Mar 18
3/13
07:28 am
mist
Form S-8 Milestone Pharmaceutical
Medium
Report
Form S-8 Milestone Pharmaceutical
3/13
07:19 am
mist
Form 8-K Milestone Pharmaceutical For: Mar 13
Medium
Report
Form 8-K Milestone Pharmaceutical For: Mar 13
3/13
07:05 am
mist
Form 10-K Milestone Pharmaceutical For: Dec 31
Medium
Report
Form 10-K Milestone Pharmaceutical For: Dec 31
2/25
04:06 pm
mist
Form 8-K Milestone Pharmaceutical For: Feb 25
Low
Report
Form 8-K Milestone Pharmaceutical For: Feb 25
2/14
09:01 am
mist
Form SCHEDULE 13G/A Milestone Pharmaceutical Filed by: RTW INVESTMENTS, LP
Low
Report
Form SCHEDULE 13G/A Milestone Pharmaceutical Filed by: RTW INVESTMENTS, LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/3
Form SC 13G/A Milestone Pharmaceutical Filed by: Venrock Healthcare Capital Partners II, L.P.
19.2%
5/9 Form 4 Milestone Pharmaceutical For: May 09 Filed by: RTW INVESTMENTS, LP 17.1%
3/6 Q4/2019 12/31/2019 EPS -0.750 ZacksConsensus -0.520 ActVsEst (0.230) - Miss 11.6%
1/2 Form 4 Milestone Pharmaceutical For: Dec 30 Filed by: WONG RODERICK 10.4%
3/24 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was downgraded by analysts at Jefferies Financial Group Inc from a "buy" rating to a "hold" rating. 8.3%
5/24 Form 8-K Milestone Pharmaceutical For: May 24 7.8%
7/8 Milestone Pharmaceuticals: Interesting, But Not Well-Differentiated From Generic Competition [Seeking Alpha] 7.8%
2/5 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $26.50 price target on the stock. 5.9%
5/21 Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting 5.7%
1/13 Form 4 Milestone Pharmaceutical For: Jan 13 Filed by: RTW INVESTMENTS, LP 5.6%
5/9 Form 4 Milestone Pharmaceutical For: May 09 Filed by: RTW INVESTMENTS, LP 17.1%
3/6 Q4/2019 12/31/2019 EPS -0.750 ZacksConsensus -0.520 ActVsEst (0.230) - Miss 11.6%
1/2 Form 4 Milestone Pharmaceutical For: Dec 30 Filed by: WONG RODERICK 10.4%
3/24 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was downgraded by analysts at Jefferies Financial Group Inc from a "buy" rating to a "hold" rating. 8.3%
5/24 Form 8-K Milestone Pharmaceutical For: May 24 7.8%
7/8 Milestone Pharmaceuticals: Interesting, But Not Well-Differentiated From Generic Competition [Seeking Alpha] 7.8%
2/5 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $26.50 price target on the stock. 5.9%
5/21 Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting 5.7%
1/13 Form 4 Milestone Pharmaceutical For: Jan 13 Filed by: RTW INVESTMENTS, LP 5.6%
TOP News Decliners
3/23
Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment
-87.1%
3/12 Form SC 13D/A Milestone Pharmaceutical Filed by: Novo Holdings A/S -8.4%
3/19 Form 4 Milestone Pharmaceutical For: Mar 02 Filed by: RTW INVESTMENTS, LP -7.3%
6/7 Milestone Pharmaceuticals (MIST) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow [Seeking Alpha] -6.1%
11/8 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.9%
5/15 Form 8-K Milestone Pharmaceutical For: May 13 -3.9%
3/6 Form S-8 Milestone Pharmaceutical -3.8%
6/3 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is now covered by analysts at Cowen Inc. They set a "buy" rating and a $32.00 price target on the stock. -3.3%
11/14 Milestone Pharmaceuticals to Present at Upcoming Investor Conferences -2.9%
10/3 Form 4 Milestone Pharmaceutical For: Oct 01 Filed by: RTW INVESTMENTS, LP -2.8%
3/12 Form SC 13D/A Milestone Pharmaceutical Filed by: Novo Holdings A/S -8.4%
3/19 Form 4 Milestone Pharmaceutical For: Mar 02 Filed by: RTW INVESTMENTS, LP -7.3%
6/7 Milestone Pharmaceuticals (MIST) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow [Seeking Alpha] -6.1%
11/8 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.9%
5/15 Form 8-K Milestone Pharmaceutical For: May 13 -3.9%
3/6 Form S-8 Milestone Pharmaceutical -3.8%
6/3 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is now covered by analysts at Cowen Inc. They set a "buy" rating and a $32.00 price target on the stock. -3.3%
11/14 Milestone Pharmaceuticals to Present at Upcoming Investor Conferences -2.9%
10/3 Form 4 Milestone Pharmaceutical For: Oct 01 Filed by: RTW INVESTMENTS, LP -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: